Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Audio By Carbonatix

BOSTON--(BUSINESS WIRE)--Jan 12, 2026--

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase 73,000 shares of its common stock to eight new employees and the grant of 218,265 restricted stock units to nineteen new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price equal to $6.88 per share, the closing price of Verastem Oncology’s common stock as reported by Nasdaq on January 6, 2026. The stock options to purchase 73,000 shares of common stock granted to eight new employees and 218,265 restricted stock units granted to nineteen new employees will vest at a rate of twenty-five percent (25%) on the one-year anniversary of the employee’s date of hire, with the remaining shares vesting quarterly over the next three (3) years in equal quarterly amounts, provided the employee continues to serve as an employee of or other service provider to Verastem Oncology on each such vesting date.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI™ FAKZYNJA™ CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260112749150/en/

CONTACT: For Investor and Media Inquiries:

Julissa Viana

Vice President, Corporate Communications and Investor Relations

[email protected]

[email protected]

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY

SOURCE: Verastem Oncology

Copyright Business Wire 2026.

PUB: 01/12/2026 04:01 PM/DISC: 01/12/2026 04:02 PM

http://www.businesswire.com/news/home/20260112749150/en